Janux Therapeutics

Janux Therapeutics, Inc. operates a preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company was founded in June 2017 and is headquartered in San Diego, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CleanSpark

Equillium Inc

Root

SoundHound AI Inc

Janux Therapeutics (JANX), SoundHound (SOUN), ROOT, Equillium (EQ) and CleanSpark (CLSK) more than doubled in February.

5 Stocks That More Than Doubled in February

If you are looking for stocks that are well positioned to maintain their recent uptrend, Janux Therapeutics, Inc. (JANX) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Recent Price Trend in Janux Therapeutics, Inc. (JANX) is Your Friend, Here's Why

SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants.

Janux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Janux Therapeutics, Inc. has positive preliminary results released from phase 1a study, using JANX007 for the treatment of patients with advanced or metastatic castration-resistant prostate cancer. With positive single-agent activity of JANX007 observed in patients with metastatic castration-resistant prostate cancer, potential to advance combination therapy with PSMA targeting agent XTANDI. It is expected that the global prostate cancer therapeutics market could reach $28.5 billion by 2032.

Janux: Additional Opportunity With JANX007 Dosing Update In The 2nd Half Of 2024

SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Announces Proposed Public Offering of Common Stock.

Janux Therapeutics Announces Proposed Public Offering of Common Stock

Janux Therapeutics unveiled promising results for a prostate cancer treatment on Tuesday, and the biotech stock nearly tripled.

Janux Stock Launches 180% On Its 'Significant Opportunity' In Prostate Cancer Treatment

Janux Therapeutics shares more than doubled in value before the bell on Tuesday after the drug developer reported encouraging interim early-stage data for its experimental therapy to treat an advanced form of prostate cancer.

Janux Therapeutics surges as trial data for prostate cancer therapy shows promise

Janux Therapeutics (NASDAQ: JANX ) stock is rocketing higher on Tuesday after the clinical-stage biopharmaceutical company posted interim results from two studies. According to a press release from Janux Therapeutics, both JANX007 and JANX008 are showing encouraging efficacy and safety data in their clinical trials.

Why Is Janux Therapeutics (JANX) Stock Up 108% Today?

SAN DIEGO--(BUSINESS WIRE)---- $JANX--PSMAxCD3-TRACTr JANX007 in mCRPC and EGFRxCD3-TRACTr JANX008 in Solid Tumors.

Janux Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for PSMAxCD3-TRACTr JANX007 in mCRPC and EGFRxCD3-TRACTr JANX008 in Solid Tumors

Janux Therapeutics, Inc. (JANX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Janux Therapeutics, Inc. (JANX) Moves 5.6% Higher: Will This Strength Last?

SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data for PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008.

Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data for PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008

SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Promotes Co-Founder Tommy DiRaimondo, Ph.D. to Chief Scientific Officer.

Janux Therapeutics Promotes Co-Founder Tommy DiRaimondo, Ph.D. to Chief Scientific Officer

The average of price targets set by Wall Street analysts indicates a potential upside of 205.5% in Janux Therapeutics, Inc. (JANX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Does Janux Therapeutics, Inc. (JANX) Have the Potential to Rally 205.5% as Wall Street Analysts Expect?

The consensus price target hints at a 220.2% upside potential for Janux Therapeutics, Inc. (JANX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts See a 220.17% Upside in Janux Therapeutics, Inc. (JANX): Can the Stock Really Move This High?

The heavy selling pressure might have exhausted for Janux Therapeutics, Inc. (JANX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Janux Therapeutics, Inc. (JANX) Loses -34.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights.

Janux Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

The average of price targets set by Wall Street analysts indicates a potential upside of 120.8% in Janux Therapeutics, Inc. (JANX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Think Janux Therapeutics, Inc. (JANX) Could Surge 120.82%: Read This Before Placing a Bet

Janux Therapeutics, Inc. (JANX) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to loss of $0.41 per share a year ago.

Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Misses Revenue Estimates

SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights.

Janux Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights

Janux Therapeutics, Inc. (JANX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

All You Need to Know About Janux Therapeutics, Inc. (JANX) Rating Upgrade to Buy

The consensus price target hints at a 120.7% upside potential for Janux Therapeutics, Inc. (JANX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Believe Janux Therapeutics, Inc. (JANX) Could Rally 120.65%: Here's is How to Trade

SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Announces Pricing of $60 Million Underwritten Offering of Common Stock and Pre-Funded Warrants.

Janux Therapeutics Announces Pricing of $60 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Announces Positive Interim Clinical Data from Phase 1a Dose Escalation for PSMA-TRACTr JANX007 and an Update on Pipeline Programs.

Janux Therapeutics Announces Positive Interim Clinical Data from Phase 1a Dose Escalation for PSMA-TRACTr JANX007 and an Update on Pipeline Programs

SAN DIEGO--(BUSINESS WIRE)---- $JANX #CD28--Janux Therapeutics Appoints Zachariah McIver, D.O., Ph.D., Vice President, Clinical Development.

Janux Therapeutics Appoints Zachariah McIver, D.O., Ph.D., Vice President, Clinical Development

Janux Therapeutics, Inc. (JANX) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to loss of $0.32 per share a year ago.

News for Janux Therapeutics Stock (JANX)